A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.

This study has been terminated.

(Due to the uncertain regulatory landscape for erythropoiesis-stimulating agents in oncology indications.)

Sponsor:

Collaborator:

Affymax

Information provided by (Responsible Party):

Takeda Global Research & Development Center, Inc.

ClinicalTrials.gov Identifier:

NCT00629876

First received: February 26, 2008

Last updated: November 29, 2011

Last verified: November 2011

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Study Completion Date:	June 2008
Primary Completion Date:	June 2008 (Final data collection date for primary outcome measure)